CTO Realty Growth Secures $57 Million in First Tranche of $250 Million Shelf Offering

---

CTO Realty Growth, Inc. (ticker: CTO‑PA) moved from registration to execution this week, filing a Form 424B5 that confirms the first $57.34 million of its planned $250 million equity offering has been sold. The filing, dated April 29, 2026, does not disclose the exact price per share, the underwriting discount, or the net proceeds after commissions – a rarity for a final prospectus supplement and a signal that the pricing mechanics remain opaque.

What the numbers say - Aggregate offering size: up to $250 million. - Shares sold to date: $57,340,024 in aggregate proceeds. - Remaining capacity: $192,659,976 still available for sale.

Because the prospectus supplement omits the per‑share price, investors cannot tell whether the tranche was priced at the high end of any earlier guidance (if any) or at a discount that would suggest tepid demand. The filing also fails to state the underwriting discount or the net cash that will land in CTO’s coffers, leaving the market to infer the economics from the syndicate’s composition and typical market spreads.

Underwriters and new sales agents The original underwriting syndicate – UBS, Wells Fargo, Jefferies, Raymond James, KeyBanc and Truist – remains at the helm. The supplement adds Cantor Fitzgerald & Co. and Huntington Securities as additional sales agents, forward sellers and forward purchasers, expanding the distribution network and potentially widening the pool of institutional buyers.

Risk factors that matter now The prospectus incorporates risk factors by reference to CTO’s most recent Form 10‑K and subsequent 10‑Q filings. While the supplement does not list new deal‑specific risks, investors should keep an eye on the usual culprits: - Dilution: New shares will increase the outstanding count, potentially diluting existing shareholders. - Lock‑up periods: Insiders may be subject to post‑offering lock‑up agreements that could affect future supply. - Overallotment (greenshoe) option: The filing does not disclose whether an overallotment option is available, but such mechanisms are common and can further increase dilution if exercised.

Use of proceeds – a blank slate The filing provides no detail on how the $57 million – or the remaining $192 million when eventually sold – will be deployed. CTO’s registration statement typically references prior filings for use‑of‑proceeds language, but the supplement itself offers no new allocation narrative. Investors will have to turn to the company’s latest 10‑K or forthcoming press releases for clues.

Market context CTO’s move comes at a time when real‑estate‑focused public offerings have been modest, with several REITs opting for secondary offerings rather than fresh IPOs. The broader equity market has shown mixed appetite for new capital, especially in sectors sensitive to interest‑rate fluctuations. Analysts covering the real‑estate space have noted that pricing at the high end of a range can be a bellwether for confidence, while pricing near the low end often signals a need for price concessions. Without a disclosed price, market participants will watch the remaining tranche closely to gauge demand.

What’s next? The $192 million still on the table could be priced in the coming weeks, potentially in multiple tranches. The added sales agents suggest CTO is positioning the offering for a broader investor base, perhaps targeting institutional funds that specialize in real‑estate assets. Until the company releases a definitive per‑share price and net‑proceeds figure, the market will read between the lines of the syndicate’s composition and the prevailing sector sentiment.

---

Key takeaways - CTO Realty Growth has sold $57.34 million of a $250 million shelf registration, but the per‑share price and net proceeds remain undisclosed. - The underwriting syndicate now includes Cantor Fitzgerald and Huntington Securities, expanding distribution reach. - Risk factors are incorporated by reference; investors should watch for dilution, lock‑up constraints, and any greenshoe option. - No specific use‑of‑proceeds allocation is provided in the supplement, leaving the purpose of the capital raise unclear. - The offering unfolds amid a cautious real‑estate market, making the pricing of the remaining tranche a key barometer of investor appetite. *